Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSKI181771X on Food Intake in Humans
NCT00600743Phase 2Terminated
- Sponsor
- St. Luke's-Roosevelt Hospital Center
- Start
- Jan 2008
- Primary completion
- Feb 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GI-181771X in bulimia nervosa (BN) (8 arms), sponsored by St. Luke's-Roosevelt Hospital Center. Primary endpoint: Food Intake for 4 mg Dose of CCK Agonist vs Placebo Meal Conditions. Started Jan 2008; status: terminated.
02
Drugs
GI-181771X
03
Conditions
bulimia nervosa (BN)
Beyond the preview
Go deeper on NCT00600743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600743.